ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE

• Main Authors: M. V. Solodun (Author), S. S. Yakushin (Author)
• Format: Book
• Published: Столичная издательская компания, 2015-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

<p><strong>Aim.</strong> To analyze the impact of the SLCO1B1*5 (c.521T> C) and LIPC (C514T) genes polymorphisms on the efficacy of atorvastatin therapy and the incidence of the combined endpoint in patients after myocardial infarction (MI).</p><p><strong>Material and methods.</strong> 121 patients with MI aged 45-75 years were included into the study. All patients were prescribed atorvastatin. A group of 65 people in whom lipid levels were studied at baseline and after 3 months of atorvastatin treatment was formed to evaluate the efficacy of statin therapy. Genetic polimorphism of SLCO1B1*5 (c.521T> C) and LIPC (C514T) was determined using polimerase chain reaction. The prognosis was assessed by clinical outcomes after 3 months of follow-up, based on the achievement of the combined endpoint MACE (Major Adverse Cardiac Events), which included cardiovascular deaths, recurrent MI, hospitalization for progressive angina, unplanned coronary revascularization.</p><p><strong>Results.</strong> Patients with SLCO1B1 c.521СC genotype had no significant reduction in the levels of atherogenic lipids (p>0.05), while patients with TT and TC genotypes demonstrated significant reduction in atherogenic cholesterol fractions (p<0.05). Allelic polymorphism of LIPC (C514T) gene has no influence on the atorvastatin treatment efficacy. The SLCO1B1 and LIPC (C514T) genes polymorphism has no impact on the three-month prognosis after MI.</p><p><strong>Conclusion.</strong> The SLCO1B1 polymorphism should be taken into consideration while personalised prescribing of atorvastatin to patients with MI.</p>

Item Description

1819-6446
2225-3653
10.1234/1819-6446-2015-1-31-35